The objectives of this study were to characterize blood pressure (BP) in acute ischemic stroke and to determine its relationship with short-term functional outcome.
O
bservational studies suggest that approximately 75% of patients with ischemic stroke have elevated blood pressure (BP) levels when measured within 24 to 48 h of onset. Mildly or moderately elevated BP frequently declines spontaneously during the first minutes or hours of focal cerebral ischemia and generally does not require urgent pharmacologic treatment. 1, 2 Data from a number of studies suggest that high BP in the acute stroke period is associated with a poor short-term outcome, 3, 4 but in other studies the opposite has been reported. 5, 6 Several explanations for the discrepancies between these results have been offered and include factors relating to observer recording of BP. 4 In an attempt to eliminate this problem, 24-h BP recording has recently been used. Moreover, although most studies have focused on the relationships between post-stroke BP elevation and outcome, few data are available to determine whether different subtypes of stroke are associated with different patterns of BP change at the time of presentation to the hospital and thereafter.
We therefore decided to investigate the relationship between BP recorded over the first 24-h after the stroke, using 24-h BP monitoring, and both the severity of the stroke and the short-term outcome in patients with acute ischemic stroke. The risk of a stroke worsening as a result of in-hospital BP reduction was also addressed.
Methods

Patients
From January 1999 to December 2003, we prospectively studied 434 consecutive patients with acute ischemic stroke admitted to the Internal Medicine Department of the Mancha Centro Hospital of Alcazar de San Juan (Spain); these patients were followed by a stroke team. Informed consent was obtained from patients or relatives. Ethical approval was obtained from the hospital ethics committee.
Patients were diagnosed as having a stroke based on World Health Organization criteria, 7 namely, rapidly developing clinical signs of focal loss of cerebral function with symptoms lasting Ͼ24 h or leading to death, with no apparent cause other than that of vascular origin. Stroke was confirmed by computed tomographic scanning of the head performed within the first 24 h after the stroke. Patients with transient ischemic attacks were not included. A control group was formed of 178 non-hypertensive patients who were not severely ill, were not dehydrated, were hemodynamically stable, presented no evidence of heart failure, and were admitted to the Internal Medicine ward over the same study period. The main clinical diagnoses in these patients were lung, gastrointestinal, and rheumatic diseases.
A clinical history and examination, including an assessment of stroke severity using the National Institutes of Health Stroke Scale (NIHSS), 8 were obtained in the study patients at the time of admission. The NIHSS was used to assess neurologic severity at day 1 and the degree of recovery at discharge or on day 7 in those patients still in hospital. Two of the investigators (JLR, EB), who were trained in administering stroke scales, evaluated the patients within 24 h of symptom onset. Patients were categorized into two groups reflecting the severity of the stroke: lacunar stroke (LS, n ϭ 205) and non-lacunar stroke (NLS, n ϭ 229). Lacunar stroke was defined according to the North American Symptomatic Carotid Endarterectomy Trial (NASCET) 9 and Fisher criteria 10 as follows: a stroke presenting as a pure motor stroke (with or without facial sparing, horizontal gaze palsy, contralateral III palsy, or contralateral VI palsy), pure sensory stroke, sensory motor stroke, dysarthria-clusmy hand, ataxic hemiparesis, cerebellar ataxia with contralateral III palsy, or pure dysarthria, with no clinical signs of cortical involvement such as aphasia, apraxia, agnosia, agraphia, or homonymous visual field defect; computed tomogram showing no abnormalities in the appropriate hemisphere or a small hypodense subcortical lesion with a diameter of Ͻ15 mm in the appropriate deep white matter of the basal ganglia.
Demographic and clinical data recorded included the following: age, sex, date and time of stroke onset, smoking, drug intake, prior Barthel index, 11 and past medical history of acute stroke, atrial fibrillation, diabetes, dyslipemia, and hypertension. Hypertension was defined a history of systolic BP (SBP) Ͼ140 mm Hg or diastolic BP Ͼ90 mm Hg before stroke onset (obtained from the records of the patient's general practitioner) or previous use of antihypertensive therapy. The results of routine hematologic and biochemical investigations including plasma glucose levels on admission, erythrocyte sedimentation rate, C-reactive protein, fibrinogen, lactate dehydrogenase, baseline total cholesterol and triglycerides, and 24-h microalbuminuria were recorded. In addition, echocardiography was performed to determine the left ventricular mass as well as other chamber measurements. Left ventricular mass was calculated according to the Devereux formula. 12 A carotid and transcranial Doppler study was also performed for full stroke classification.
Twenty-Four-Hour BP Monitoring
An automated oscillometric device (model 90207, SpaceLabs, Redmond, WA) was placed in the non-dominant arm within 24 h of stroke onset. Patients were not included in the study if the time of stroke onset was unknown. The timing to begin BP monitoring was as follows: Ͻ6 h of stroke onset, 52% of the patients; 6 to 12 h, 36%; and 12 to 24 h, 12%. The accuracy of this device was established according to criteria proposed by the British Hypertension Society. 13 Either a large adult (15 7 ϫ 32 cm) or normal adult (12 ϫ 23 cm) cuff size was used, as appropriate for the subject's mid-upper-arm circumference. Blood pressure readings were obtained every 15 min throughout the 24-h period, allowing approximately 90 readings to be taken during the monitoring period studied. Mean daytime (7:00 AM to 11:30 PM) and night-time (11:30 PM to 7:00 AM) BP readings were also analyzed to determine nocturnal BP falls and the "dipping" or "non-dipping" status, defined as nocturnal BP (systolic or diastolic) fall Ͼ10% or Ͻ10%, respectively.
Mean arterial BP (MAP) was calculated by the equation
No other clinical procedures were performed on the same day as the BP monitoring. Patients were excluded if data capture was Ͻ70%.
Antihypertensive Treatment
We adhered to the American Heart Association consensus 14 for antihypertensive treatment on day 1, withholding antihypertensive agents unless DBP was Ͼ120 mm Hg or SBP Ͼ220 mm Hg. On day 2, antihypertensive therapy was administered to those patients meeting criteria for arterial hypertension based on the initial 24-h recordings (ie, average 24-h SBP Ͼ135 mm Hg or 24-h DBP Ͼ85 mm Hg) 15 to achieve a progressive fall in the BP. In these patients, captopril (12.5 mg three times daily, titrated to a maximal dose of 150 mg) was administered; when angiotensin-converting enzyme inhibitors were contraindicated, amlodipine (2.5 mg twice daily up to a maximal dose of 5 mg twice daily) was administered. Twenty-four-hour BP monitoring was repeated in those stroke patients still in hospital on day 7 (n ϭ 322).
Outcome Measures
To analyze the impact of BP and of clinical, biochemical, and echocardiographic findings on outcome, patients were classified on day 7 (or on discharge if this occurred earlier) using the modified Rankin scale 16 to evaluate the degree of disability, forming two groups: 1) good outcome (scores 0 to 3), ranging from no significant disability despite symp-toms to moderate disability (requiring some help, but able to walk without assistance); and 2) poor outcome (scores 4 to 6), from moderate or severe disability (unable to walk without assistance and unable to attend to own bodily needs without assistance) to death. Death was considered only when this occurred in the hospital.
Data Analysis
Continuous variables are expressed as means Ϯ SD and were compared using an unpaired or paired Student t test. Categorical variables were compared using the 2 test. The Mann-Whitney test was used to compare continuous variables showing a non-normal distribution. Univariate logistic analysis was performed to determine the influence of independent variables on outcome, with patient outcome being the dependent variable, dichotomized into good or poor outcome. Independent variables included following: age, gender, Barthel index, NIHSS score, past history of stroke, previous therapy, cerebrovascular risk factors (hypertension, diabetes mellitus, hypercholesterolemia, atrial fibrillation), biochemical data (erythrocyte sedimentation rate, fibrinogen, uric acid, plasma glucose, total cholesterol, triglycerides, lactate dehydrogenase, C-reactive protein, 24-h urine microalbuminuria), echocardiographic data (left ventricular hypertrophy), timing to 24-h BP monitoring onset after stroke (day 1), 24-h BP recordings (days 1 and 7), and antihypertensive therapy during hospital stay. A multivariate analysis was then performed with a stepwise forward regression model, in which each variable with a P value of Յ .05 (based on the univariate analysis) was entered into the model. Blood pressure and HR reduction at day 7 was considered with a cut-off of 5 mm Hg and 5 beats/min, respectively, with multivariate analysis performed for the 322 patients with day 7 recordings. All significance tests were two-tailed with an ␣ level of 0.05.
Results
Lacunar Versus Non-Lacunar Stroke Patients and Control Group
Mean age and NIHSS score were higher and the Barthel index lower in NLS patients (n ϭ 229) than in LS patients (n ϭ 205): 69 Ϯ 10 years v 75 Ϯ 9 years, P Ͻ .001; and 12.7 Ϯ 7.1 v 3.6 Ϯ 1. There were no differences in the mean age, gender, and BMI between stroke patients and control subjects: age, 72 Fig. 1]) , HR being higher in control than in LS patients (71 Ϯ 12 v 76 Ϯ 13 beats/min, P Ͻ .001), with no significant differences from values in NLS patients (71 Ϯ 13 beats/min).
Analysis of Prognostic Subgroups of Stroke
Demographic and clinical data from good-outcome stroke patients (GOS, n ϭ 346) and poor-outcome stroke patients (POS, n ϭ 88) are shown in Table 1 . The mean age and NIHSS score were higher and the Barthel index was lower in POS than in GOS patients. In the POS group, 40 patients (45%) died; in the GOS group, no patient died. There were no differences in the timing to BP monitoring after stroke onset between groups.
The 24-h SBP and HR measured on day 1 were significantly higher in POS than in GOS patients ( Table 2 ). The former group also showed a less pronounced fall in nocturnal BP and HR, with the rate of dippers being 65% in GOS v 33% in POS (P Ͻ .001).
Clinical and 24-h BP Changes on Day 7
Of the 322 patients evaluated by 24-h BP monitoring on day 7, 186 patients had received antihypertensive treatment; in these patients. the 24-h SBP and DBP fell significantly (148 Ϯ 21 to 139 Ϯ 23 mm Hg and 79 Ϯ 12 to 72 Ϯ 14 mm Hg, respectively, P Ͻ .001). In the untreated patients, 24-h SBP showed a significant decrease (130 Ϯ 18 to 127 Ϯ 17 mm Hg, P Ͻ .001). Antihypertensive drugs were given to 62% of poor-outcome stoke patients v 36% in the good-outcome stroke group (P Ͻ .01). Patients Results from univariate and multivariate analysis are shown in Table 3 . Multivariate analysis of prognostic factors for short-term outcome in stroke patients showed that NIHSS score (odds ratio [OR] ϭ 1.08, 95% confidence interval [CI] ϭ 1.04 to 1.13), SBPϾ160 mm Hg (OR ϭ 2.35, 95% CI ϭ 1.10 to 5.52) and plasma glucose levels Ͼ125 mg/dL (OR ϭ 1.88, 95% CI ϭ 1.03 to 3.57) were adverse prognostic factors for outcome and that a decrease in SBP on day 7 was a protective factor against an unfavorable outcome (OR ϭ 0.46, 95% CI ϭ 0.24 to 0.88).
Discussion
Several observational studies have reported the relationship between BP on admission and the subsequent outcome in acute stroke. The interpretation of these studies is difficult for several reasons: many do not distinguish between ischemic stroke and primary intracerebral hemorrhage; they are retrospective or of small size; or they do not assess the effects in different patient subgroups. [17] [18] [19] [20] [21] Nonetheless, high SBP has usually been associated with an DBP ϭ diastolic blood pressure; ESR ϭ erythrocyte sedimentation rate; HR ϭ heart rate; LDH ϭ lactate dehydrogenase; SBP ϭ systolic blood pressure.
increased risk of death or dependency. [22] [23] [24] Intermediate events may explain this relationship because the risks of early recurrence and fatal cerebral edema have each been positively associated with SBP on admission. 25 Furthermore, changes in sympathovagal balance in favor of increased sympathetic activity are well established after acute stroke and may predispose to myocardial infarction and cardiac arrhytmias as possible mechanisms leading to an increased mortality. Recent studies suggest, however, that a reduction in BP in these patients can be associated with a poor outcome, probably due to a reduction in cerebral perfusion around the infarcted zone. 26, 27 There are few studies regarding BP behavior in different subgroups of stroke severity. In a study in 92 patients with acute ischemic stroke, it was found that patients with the highest BP on admission presented the best neurologic outcomes evaluated by means of the NIHSS on day 7; this applied in particular to patients with lacunar infarcts. 26 We observed significant higher values of BP in non-lacunar than in lacunar stroke patients. Moreover, the rise in BP had prognostic significance, with poor outcome seen in those patients with higher 24-h BP levels on day 1. Thus, it seems that post-stroke hypertension may represent a pathophysiologic response to maintain or to enhance perfusion of reversibly damaged cerebrum during the first hours after stroke, and this may also be a marker of stroke severity and the risk of further clinical progression.
Despite the prevalence of arterial hypertension after stroke, its optimal management has not been established. In our series, approximately 50% of patients admitted with stroke were taking regular antihypertensive therapy. Thus, the question arises as to whether these drugs should be stopped and when would be the appropriate time to reintroduce therapy. Traditionally, antihypertensive therapy has been delayed for the first days or even 1 to 2 weeks after stroke because of theoretical concerns about impaired cerebral flow autoregulation and hence the risk of clinical deterioration, especially in patients with long-term hypertension; and current guidelines do not state the optimal timing of antihypertensive therapy. 28, 29 Few clinical studies are available to guide clinicians. A Cochrane review regarding deliberate alteration of BP within 2 weeks of stroke onset found five small trials involving a total of 218 patients randomized to nimodipine, nicardipine, captopril, clonidine, glyceril trinitrate, or perindopril versus placebo or control treatment. The limited data made it impossible to assess the relationship between BP and clinical outcome. 30 Although our study did not address the dilemma of when to treat (or not to treat) a BP rise in acute ischemic stroke, we found that SBP reduction during hospital stay was a marker of good outcome. At entry, patients with good outcome had less neurologic damage (based on NIHSS score) and lower SBP than patients with poor outcome. In addition, patients with poor outcome had been more frequently treated with antihypertensive drugs because they had higher SBP values, but they showed a lower fall in BP than the stroke group with good outcomes. This may suggest that patients with mild neurologic damage and a mild BP rise are prone to BP decline, either spontaneously or with antihypertensive treatment. Thus, BP reduction during the first days after an acute stroke seems to be associated with less stroke severity, whereas BP rise in patients with deteriorating strokes may be a compensatory mechanism to avoid a decline in cerebral blood flow; this mechanism might be sympathetically mediated, as these patients also maintain higher HR levels than patients with less severe strokes.
Certain limitations of our study require explanation. Allocation to hypotensive medication was not randomized, and the question of optimal BP can ultimately be answered only by appropriate prospective randomized intervention trials. These trials, however, will be difficult to conduct because the current treatment guidelines already advocate high BP or cerebral perfusion pressure in these patients. 28, 29 In addition, patients with criteria of arterial hypertension by 24-h BP monitoring on day 1 received antihypertensive therapy, which makes the significant effect of short-term BP lowering in predicting outcome more powerful.
We conclude that the initial rise in BP is proportional to the clinical severity of stroke at presentation, as patients with non-lacunar strokes showed higher BP levels that those with lacunar strokes. It can be suggested that this might be a physiologic response to cerebral ischemia. In addition, the decline of BP during the first days after an acute ischemic stroke seemed to be the consequence of a lesser severity of stroke. Because optimal management of BP during the acute phase of ischemic stroke is not established, there is a need for a sufficiently large randomized clinical trial to address the optimal management of pa- OR ϭ odds ratio; other abbreviations as in Tables 1 and 2 .
tients with acute ischemic stroke and different degrees of neurologic damage.
